Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
AstraZeneca and Merck Sharp & Dohme Corp.
Description:
Prostate cancer is the most diagnosed non-cutaneous cancer in men in
the United States (US) and remains the second leading cause of
cancer deaths among American men, with an estimated 191,930 new
cases diagnosed in 2020. Prostate cancer deaths are typically the
result of castration-resistant prostate cancer (CRPC), and most
patients will eventually experience disease progression despite
castration, with a median duration of response of 12–24 months.
About 40 percent of these patients have prostate cancer that is also
associated with a rising prostate-specific antigen (PSA) level that
has not spread to other parts of the body. The danger that can
occur, if not caught early, is that 33% of those men could have the
cancer spread to other parts of the body.
Upon completion of this
activity, participants will be able to:
-
Explore clinical guidelines and new
evidence for appropriate treatment decision-making for prostate
cancer
-
Assess the sequencing of novel
therapies and be able to identify patient progression of disease
by PSA, imaging, signs and symptoms
-
Discuss current and emerging
treatments for patients with prostate cancer based on clinical
trial safety and efficacy data
-
Analyze the unique mechanism of
action and adverse effects of new and existing agents, including
PARP inhibitor-based therapies
-
Examine the managed care
considerations of current and emerging treatments by
understanding the use of a multidisciplinary team to implement
personalized strategies
|
Faculty: |
Scott T. Tagawa, MD, MS,
FACP
Professor of Medicine & Urology
Medical Director, Genitourinary Oncology Research
Program
Leader, GU Disease Management Team, Meyer Cancer Center
Weill Cornell Medical College |
|
Disclosure:
|
Dr. Tagawa
has served as a consultant for Sanofi, Medivation/Astellas,
Dendreon, Janssen, Genentech, Bayer, Endocyte, Eisai,
Immunomedics, Karyopharm, Abbvie, Tolmar, Seattle
Genetics, Amgen, Clovis, QED, Pfizer, AAA/Novartis,
Clarity, Genomic Health, POINT Biopharma, Blue Earth
Diagnostics, AIkido Pharma, Telix Pharma, and Convergent
Therapeutics. He has received grant/research support
from Sanofi, Medivation, Astellas, Janssen, Amgen,
Progenics, Dendreon, Lilly, Genentech, Newlink, BMS,
Inovio, and AstraZeneca. He has received royalties from
Gilead/Immunomedics. He owns stock in Alkido. His
presentation has been reviewed for any bias. |
|
Planning Committee: |
Bill Williams,
MD has no financial relationships with ineligible
companies to disclose.
Jeremy Williams has no financial relationships with
ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial
relationships with ineligible companies to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by an educational grant from
AstraZeneca and Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |